Gujarat Magazine

Ankylosing spondylitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | UCB Inc., AbbVie, Pfizer, Amgen/Pfizer, Janssen Biotech, Pozen, Novartis and Others.

 Breaking News
  • No posts were found

Ankylosing spondylitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | UCB Inc., AbbVie, Pfizer, Amgen/Pfizer, Janssen Biotech, Pozen, Novartis and Others.

April 17
14:06 2021
Ankylosing spondylitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | UCB Inc., AbbVie, Pfizer, Amgen/Pfizer, Janssen Biotech, Pozen, Novartis and Others.

Ankylosing spondylitis Pipeline

 

Ankylosing spondylitis (AS), also called as Bechterev’s disease is a form of arthritis that primarily affects the spine, although other joints may also be involved. It causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort. It is a type of axial spondyloarthritis (axSpA) that refers to a particular form of spondyloarthritis in which the predominant symptom is inflammatory back pain.

Ankylosing spondylitis has no known specific cause, though genetic factors seem to be involved. In particular, people who have HLA-B27 gene are at increased risk of developing ankylosing spondylitis.

On the basis of severity, AS is classified as mild or early AS (stable AS) and severe or advanced AS (active). Early AS usually starts with dull pain in the lower back and the back stiffness, whereas severe AS is associated with continuous inflammation that leads to scarring and permanent damage.

DelveInsight’s “Ankylosing Spondylitis Pipeline Insight” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Ankylosing Spondylitis pipeline landscapes. It comprises Ankylosing Spondylitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Ankylosing Spondylitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Ankylosing Spondylitis pipeline products.

 

Key pharma players involved in Ankylosing spondylitis market are:

  1. UCB Inc.
  2. AbbVie
  3. Pfizer
  4. Amgen/Pfizer
  5. Janssen Biotech
  6. Pozen
  7. Novartis
  8. Merck
  9. Horizon Pharma
  10. Iroko Pharmaceuticals
  11. And Many More

 

Request for free Sample Report: https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight

 

Key benefits of the Ankylosing Spondylitis report:

  • In the coming years, Ankylosing Spondylitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Ankylosing Spondylitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Ankylosing Spondylitis. Launch of emerging therapies will significantly impact the Ankylosing Spondylitis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Ankylosing Spondylitis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Request for free Sample Report: https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight

“The United States accounts for the highest prevalent population of Ankylosing Spondylitis, followed by EU5 and Japan.”

 

Ankylosing Spondylitis Drugs involved are:

  1. Cimzia
  2. Humira
  3. Celebrex
  4. Enbrel
  5. Simponi
  6. Vimovo
  7. Cosentyx
  8. Arcoxia
  9. Rayos
  10. Indocin
  11. And Many More

 

Request for free Sample Report: https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight

 

Table of contents:

1. Report Introduction

2. Ankylosing Spondylitis 

3. Ankylosing Spondylitis Current Treatment Patterns

4. Ankylosing Spondylitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Ankylosing Spondylitis Late Stage Products (Phase-III)

7. Ankylosing Spondylitis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Ankylosing Spondylitis Discontinued Products

13. Ankylosing Spondylitis Product Profiles

14. Ankylosing Spondylitis Key Companies

15. Ankylosing Spondylitis Key Products

16. Dormant and Discontinued Products

17. Ankylosing Spondylitis Unmet Needs

18. Ankylosing Spondylitis Future Perspectives

19. Ankylosing Spondylitis Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/gujaratmagazine.in/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share